biostudies-literatureUnknown18(3)Peng DExploring the regulatory mechanism of PD-L1 in renal cancer is one of the key strategies to improve the response of renal cancer patients to checkpoint blockade therapy. In this study, the synergistic effect of ascorbic acid (vitamin C) supplementation and the impact of TET2 depletion on anti-PD-L1 therapy were determined in xenograft model experiments. Lymphocyte infiltration and chemokine expression were determined using flow cytometry and qRT-PCR. To determine the downstream targets of TET2, we performed hMeDip-seq and RNA-seq analyses. The molecular mechanism was further confirmed by hMeDip-qPCR, MeDip-qPCR, bisulfite sequencing, Western blotting, qRT-PCR and xenograft model experiments in vitro and in vivo. The present study demonstrated that ascorbic acid enhanced the eInternational journal of biological sciences995-1007https://www.ebi.ac.uk/biostudies/studies/S-EPMC8771844biostudies-literatureAscorbic acid induced TET2 enzyme activation enhances cancer immunotherapy efficacy in renal cell carcinoma.PMC8771844Li XZhou LHe SPeng DGe GWang SHe ACi WXia DfalseAscorbic acid induced TET2 enzyme activation enhances cancer immunotherapy efficacy in renal cell carcinoma.Exploring the regulatory mechanism of PD-L1 in renal cancer is one of the key strategies to improve the response of renal cancer patients to checkpoint blockade therapy. In this study, the synergistic effect of ascorbic acid (vitamin C) supplementation and the impact of TET2 depletion on anti-PD-L1 therapy were determined in xenograft model experiments. Lymphocyte infiltration and chemokine expression were determined using flow cytometry and qRT-PCR. To determine the downstream targets of TET2, we performed hMeDip-seq and RNA-seq analyses. The molecular mechanism was further confirmed by hMeDip-qPCR, MeDip-qPCR, bisulfite sequencing, Western blotting, qRT-PCR and xenograft model experiments in vitro and in vivo. The present study demonstrated that ascorbic acid enhanced the e2022-01-01T00:00:00Z20222026-06-19T04:48:54.361Z2025-04-06T09:15:00.726ZS-EPMC87718443517353210.7150/ijbs.67329